retatrutide ema approval status 2025 approval: FDA status, clinical trial results, and when it could be available Retatrutide approval: FDA status, clinical
Description
The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies
Because Medicare patients often face overlapping risks such as chronic kidney disease and cardiovascular complications, multi-indication agents such as the SGLT2s remain an important complementary option alongside GLP1s
In this blog, which also forms one of the chapters of an ebook, I outline the programme and tools our patients use in our cardiometabolic clinic.
In this episode of Black Doctors Speak, Dr
Noticing hair thinning during GLP-1 weight loss
Weight loss treatment changes more than weight
